Ghofrani, Hossein-ArdeschirHossein-ArdeschirGhofraniGomez Sanchez, Miguel-AngelMiguel-AngelGomez SanchezHumbert, MarcMarcHumbertPittrow, DavidDavidPittrowSimonneau, GéraldGéraldSimonneauGall, HenningHenningGallGrünig, EkkehardEkkehardGrünigKlose, HansHansKloseHalank, MichaelMichaelHalankLangleben, DavidDavidLanglebenSnijder, Repke JRepke JSnijderEscribano Subias, PilarPilarEscribano SubiasMielniczuk, Lisa MLisa MMielniczukLange, Tobias JTobias JLangeVachiéry, Jean-LucJean-LucVachiéryWirtz, HubertHubertWirtzHelmersen, Douglas SDouglas SHelmersenTsangaris, IraklisIraklisTsangarisBarberá, Joan AJoan ABarberáPepke-Zaba, JoannaJoannaPepke-ZabaBoonstra, AncoAncoBoonstraRosenkranz, StephanStephanRosenkranzUlrich, SilviaSilviaUlrichSteringer-Mascherbauer, ReginaReginaSteringer-MascherbauerDelcroix, MarionMarionDelcroixJansa, PavelPavelJansaŠimková, IvetaIvetaŠimkováGiannakoulas, GeorgeGeorgeGiannakoulasKlotsche, JensJensKlotscheWilliams, EvgeniaEvgeniaWilliamsMeier, ChristianChristianMeierHoeper, Marius MMarius MHoeperPING-HUNG KUOCHO-KAI WUYEN-HUNG LINJIUNN-LEE LINCHI-SHENG HUNG2021-05-112021-05-112021-0309546111https://scholars.lib.ntu.edu.tw/handle/123456789/560671The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice.enChronic thromboembolic pulmonary hypertension; Clinical practice; Real-world; Registry; Riociguat; Safety[SDGs]SDG3ambrisentan; bosentan; guanylate cyclase; iloprost; macitentan; prostacyclin; prostanoid; riociguat; treprostinil; pyrazole derivative; pyrimidine derivative; riociguat; adverse event; aged; Article; chronic thromboembolic pulmonary hypertension; clinical practice; clinical trial; cohort analysis; combination drug therapy; disease registry; dizziness; drug safety; dyspnea; faintness; female; heart right ventricle failure; hemoptysis; human; hypotension; lung hemorrhage; major clinical study; male; Medical Dictionary for Regulatory Activities; monotherapy; multicenter study; peripheral edema; phase 3 clinical trial; pneumonia; priority journal; prospective study; pulmonary hypertension; randomized controlled trial; chronic disease; complication; data analysis; lung embolism; middle aged; multicenter study (topic); pulmonary hypertension; randomized controlled trial (topic); recurrent disease; register; safety; time factor; treatment outcome; Aged; Chronic Disease; Data Analysis; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Recurrence; Registries; Safety; Time Factors; Treatment Outcomejournal article10.1016/j.rmed.2020.106220335403402-s2.0-85100409820